PRIA Logo™
119-hr-7212119th CongressWALLET

Hemp Enforcement, Modernization, and Protection Act

Sponsored By: Representative Griffith, H. Morgan [R-VA-9]

Introduced

Summary

Would create a new federal regulatory category for cannabinoid hemp products. It would set national definitions, product-form rules, premarket notifications, manufacturing and testing standards, age limits, recall authority, and enforcement tools for inhalable, oral, and topical cannabinoid hemp items.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

11 provisions identified: 3 benefits, 2 costs, 6 mixed.

New facility registration and inspections

If enacted, facilities that make, pack, import, label, or hold cannabinoid hemp products would have to register with the Secretary. Existing facilities would have to register within 1 year, and new facilities within 60 days of first engaging in activity. Registrations would repeat every two years and could be suspended for serious safety risks. The Secretary could inspect facilities, detain suspect products up to 20 days (up to 30 days in some cases), and treat refusal to permit a foreign inspection within a short agreed period (default 24 hours) as a basis to deny entry.

Product listings and inhalable premarket notices

If enacted, the person responsible for each cannabinoid hemp product would have to list it with the Secretary. Non-inhalable products would be listed within 120 days of first marketing and inhalable products within 90 days. Currently marketed products would meet special one-year listing deadlines. Listings would include facility registration numbers, ingredients, cannabinoid amounts, label copy, and must be updated yearly. New inhalable products would need to submit premarket formulation and labeling information 90 days before sale; existing inhalables would need to report within 60 days after enactment.

New manufacturing and inhalable rules

If enacted, the Secretary would set uniform manufacturing and testing rules for cannabinoid hemp products and could rely on recognized third-party standards. Inhalable products would face strict rules on permitted ingredients, solvents, and pesticide residues. Most aerosol inhalable products would have to be sold in prefilled, nonrefillable cartridges that meet content limits. The rules would improve product safety but would also require new testing, possible reformulation, recordkeeping, and inspections.

Mandatory recalls and new penalties

If enacted, the Secretary could require a voluntary recall and then order a mandatory recall when a cannabinoid hemp product poses a reasonable probability of serious health harm or death. Responsible parties would get an initial chance to recall; an informal hearing must occur within 10 days after a mandatory order. The bill would create new prohibited acts, bar retail sales to persons under 21, allow public notice of recalls, and add criminal penalties for knowing violations, including up to 10 years in prison or fines.

Default cannabinoid content limits

If enacted, the Secretary would have to propose a rule within 60 days and finalize content limits within 3 years for cannabinoids in oral, inhalable, and topical products. If no final rule appears in 3 years, default limits would apply: oral products 10 mg per serving and 50 mg per package; inhalable and topical products 100 mg per serving and 500 mg per package; total intoxicating cannabinoids 5 mg per serving and 30 mg per package. The Secretary could set different numeric limits by final rule.

New rules for adulterated products

If enacted, the bill would define when a cannabinoid hemp product is 'adulterated.' Products would be adulterated if they are contaminated, made in insanitary conditions, or exceed the bill's cannabinoid limits. Products would also be adulterated if they include certain added substances (for example, alcohol, caffeine, tobacco, nicotine, or melatonin) or if the product refuses inspection. Adulterated products could be removed from sale.

New cannabinoid advisory committee

If enacted, the bill would create a 16-member Cannabinoid Hemp Products Advisory Committee to advise the Secretary. Members would include FDA officials, doctors and scientists, a state regulator, a public member, industry nonvoting consultants, and a grower. Most members would be barred from taking tobacco-industry payments during service and for 18 months before. The Committee would report each year to Congress with recommendations on content limits.

Defines cannabinoids and public list

If enacted, the bill would define 'cannabinoid' broadly to include named cannabinoids, synthetic equivalents, and plant-derived CB1/CB2 agonists. The Secretary would publish an initial public list on HHS's website within 1 year and could update it periodically. The list would clarify which chemicals are covered, which helps consumers and regulators but could require manufacturers to reformulate or relabel products.

New labeling and misbranding rules

If enacted, packaged cannabinoid hemp products would need specific labels. Labels would have maker contact, an amount statement, a front-of-package statement that it is a cannabinoid hemp product, ingredient lists, serving size and number of servings for oral products, and per-serving and per-package cannabinoid amounts. Labels would need allergen and risk warnings and a QR code to link to testing results. Multi-serving packages would need tamper evidence and packaging must not appeal to children. Products made in unregistered facilities or not listed would be misbranded.

Which cannabinoid products are covered

If enacted, products that contain or claim to contain listed cannabinoids and are for people or animals would be called 'cannabinoid hemp products.' The bill would exclude approved drugs, licensed biologics, approved devices, regulated food additives used as allowed, and certain cultivated Cannabis sativa L. plants. The definitions would clarify which products follow the new rules, shifting regulatory duties onto makers of covered products.

Which cannabinoid products would be banned

If enacted, the bill would define inhalable, oral, and topical product types and set rules for when a product is 'prohibited.' For example, inhalable and topical products would be prohibited if their inhalable or topical material exceeded 0.3% total intoxicating cannabinoid by weight. Oral products would be prohibited if they exceeded the per-serving or per-package intoxicating thresholds set by rule (or the defaults). The bill would also bar products that use only non-naturally occurring cannabinoids or that are for food-producing animals.

Sponsors & CoSponsors

Sponsor

Griffith, H. Morgan [R-VA-9]

VA • R

Cosponsors

  • Rep. Veasey, Marc A. [D-TX-33]

    TX • D

    Sponsored 1/22/2026

  • Rep. Crenshaw, Dan [R-TX-2]

    TX • R

    Sponsored 2/4/2026

  • Rep. Garcia, Sylvia R. [D-TX-29]

    TX • D

    Sponsored 2/4/2026

  • Rep. Vindman, Eugene Simon [D-VA-7]

    VA • D

    Sponsored 2/11/2026

  • Rep. Baird, James R. [R-IN-4]

    IN • R

    Sponsored 2/11/2026

  • Rep. James, John [R-MI-10]

    MI • R

    Sponsored 5/13/2026

  • Rep. Grijalva, Adelita S. [D-AZ-7]

    AZ • D

    Sponsored 6/2/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation